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proved by using appropriate biomarkers or 
diagnostics, to determine eligibility prior to 
administration of treatment. As such, thera-
pies developed using the Precision Medicine 
approach may be able to command a higher 
price, driven by a greater value provided to 
each treated patient, and by reducing waste 
associated with treating patients not gaining 
benefit from the therapy. In addition, from a 
regulatory perspective, there may be fewer 
adverse events and therefore less potential 
for market withdrawal and fewer label re-
strictions; as well from a payer perspective, 
reimbursement hurdles may be lower due 
to elimination of costs associated with non-
response to therapy.
The success of Precision Medicine is depen-
dent on the appropriate selection of projects 
that benefit from its application. Ideally the 
following criteria are fulfilled:
 - Strong human biology data package in-
dicating that the drug target is a critical 
driver of disease and modulation of its 
activity is likely to produce a significant 
clinical benefit.
 - Evidence of downstream pharmacodyna-
mic effects as a consequence of engaging 
the target.
 - Efficacy or safety biomarkers predicti-
ve of clinical benefit, allowing popula-
tion stratification and diagnostics deve-
lopment if appropriate.
Biomarkers for patient stratification are typi-
cally not validated until phase II clinical 
trials, although it is ideal if they are available 
earlier. For the biomarker to be validated for 
use in patient selection, a clinically signifi-
cant improvement in outcome (therapeutic 
index) associated with the biomarker is re-
quired. Validated biomarkers may be transla-
ted into a companion diagnostic used to iden-
tify a subpopulation that should (or should 
not) receive treatment if appropriate.
PRECISION MEDICINE
Precision Medicine [1-3] is an approach to 
discovering and developing medicines and 
vaccines that deliver superior outcomes for 
patients, by integrating clinical and molecular 
information to understand the biological basis 
of disease creating a GPS map of human dise-
ase. This approach should lead to selection of 
better drug targets and identification of patient 
populations that have better clinical outcomes 
due to higher likelihood of response or lack of 
adverse events. When appropriate, these new 
treatments are focused on a particular sub-
group of patients with certain phenotypic or 
genetic hallmarks that make them more likely 
to respond beneficially.
STRATEGIC APPLICATION 
OF PRECISION MEDICINE
One of the emerging challenges in the access 
and uptake of pharmaceuticals developed by 
the traditional drug development model is the 
inability to accurately pinpoint the specific 
population, in which the drug is supposed to 
be used for optimal benefit. This is particu-
larly relevant for certain primary care disea-
ses (e.g., hypertension, mild asthma, seasonal 
allergy, upper respiratory infections etc) whe-
re generic versions of effective treatments 
are increasingly available and unmet need 
is generally lower than in specialty and on-
cology areas. Increasingly, payers and reim-
bursement agencies around the world require 
submission of data cuts on the subpopulation, 
where many of the existing treatments may 
not be effective, and as such reimbursement 
and utilization of a novel treatment would be 
appropriate.
Treatments developed using the Precision 
Medicine approach may be perfectly suited 
for these types of situations, as the predic-
tability of response can be significantly im-
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Ideally, a drug and its companion diagnostic 
are developed and filed for approval contem-
poraneously based on the clinical relevance 
and technical performance criteria establi-
shed using data from the clinical development 
program (as was done for Herceptin®, Xalko-
ri®, and Zelboraf®). Contemporaneous deve-
lopment of a distinct FDA approved compa-
nion diagnostic with each single precision 
medicine is a cumbersome and expensive 
task that can slow the advance and uptake of 
novel life saving drugs. The recent progress 
in regulatory clearance of DNA sequencing 
platforms, opens the door for simpler deve-
lopment of multiplexed companion diagno-
stic assays for novel targeted treatments e.g., 
cancer drugs against mutationally activated 
oncogenes.
PRECISION MEDICINE 
CASE STUDIES
Example #1. Developing 
a cancer therapeutic for a 
targeted population: Xalkori®
Oncology constitutes the frontier of Precision 
Medicine, with patient selection defined by 
gene fusions (e.g. Gleevec®, Xalkori®), so-
matic mutations (e.g. Zelboraf®) or protein 
over-expression (e.g. Herceptin®). Xalkori® 
a.k.a. Crizotinib was originally developed 
as a cMET kinase inhibitor, but also inhi-
bits ALK and ROS kinases. In 2007 it was 
discovered that ~ 5% of patients with non-
small cell lung cancer (NSCLC) express an 
EML4-ALK fusion protein in which ALK 
kinase is constitutively active [4]. Phase I cli-
nical trials were rapidly amended to include a 
molecularly defined EML4-ALK cohort. Im-
pressive efficacy (~ 60% ORR) allowed rapid 
progress from Phase I directly to Phase III. 
Contemporaneous FDA approval of Xalkori® 
and a diagnostic FISH test (Vysis) was achie-
ved in August 2011 in a record five years after 
the start of the first clinical studies, and with 
relatively few patients. Had the clinical trials 
been conducted in a non-selected NSCLC pa-
tient population, the strong clinical efficacy 
would not have been evident (number needed 
to treat (NNT) of ~ 40 for the broad popula-
tion vs. ~ 2 for the EML4-ALK population), 
and this compound most likely would never 
have become a medicine.
Unfortunately most patients become resistant 
to Xalkori® (and other targeted therapies). Re-
sistance mutations can be identified by next 
generation sequencing (NGS) and used to 
inform the design of second generation com-
pounds. Furthermore, combining chemothe-
rapy or targeted therapies with harnessing the 
immune system with “checkpoint modulators” 
or by potentiating patient T Cells with recom-
binant proteins or gene therapy promises to 
dramatically increase the number of patients 
that obtain real cures using Precision Medici-
ne. The use of “liquid biopsies” e.g. circula-
ting tumor cells for early detection of cancer 
and monitoring of response as well as more 
precise diagnostics such as standard sequen-
cing of the tumor and monitoring the state of 
tumor infiltrating lymphocytes also promise to 
further improve outcome for patients. At the 
point of care multiplexed diagnostic assays 
particularly those employing NGS technology 
will become increasingly important due to li-
mited sample availability and the practicality 
of only one or a few diagnostic tests.
Example #2. Leveraging insight 
from human genetics: PCSK9
The rapid progress in human genetics enables 
easy identification of the genetic cause for 
many diseases with “extreme phenotypes”. 
For example, individuals with a mutation in 
the PCSK9 gene have very low LDL-chole-
sterol and significantly reduced incidence of 
CV disease but are otherwise normal [5]. Ba-
sed on these findings several companies are 
developing anti-PCSK9 antibodies. One such 
antibody, RN316, shows significant and long 
lasting declines in LDL- cholesterol in many 
patients with elevated LDL-cholesterol. Ano-
ther application of genetics is in functional 
analysis of gene variants identified by gene-
tic studies. Differentiated iPS cell lines with 
distinct variants of the target gene introduced 
by genome editing (with TALEN, CRISPR 
or similar approaches) is becoming a main 
stream tool for interrogating the functional 
consequences of gene variants in a physiolo-
gically relevant setting.
Example #3. Understanding 
the molecular basis of adverse 
drug events to create safer 
therapeutics: Tysabri®
Precision Medicine can be employed to de-
liver better clinical outcomes by selecting 
patients for treatment to avoid drug-related 
adverse events. An analysis of drugs with 
pharmaco-genomic Biomarkers in their la-
bel demonstrated that 62% of the biomarkers 
are used for exclusion of patients or dose 
adjustment to avoid certain adverse events 
[6]. The majority of safety biomarkers detect 
polymorphisms in genes for metabolizing 
enzymes or drug transporters in order to en-
sure adequate drug exposure. Other safety 
biomarkers focusing on idiosyncratic toxici-
ty frequently measure enzyme deficiencies or 
immune response (e.g. HLA genes). A parti-
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cular impactful example is that of Tysabri®, 
an immunosuppressive α4-integrin antibody 
for treatment of Multiple sclerosis. The rare 
and sometimes fatal occurrence of PML cau-
sed by JC Virus was threatening this multi-
billion dollar franchise and the availability 
of an effective therapeutic to patients. The 
finding that 99% of PML cases could be pre-
dicted by anti-JC virus antibodies provided 
an effective way of excluding patients that 
may experience PML [7].
Example #4. Importance 
of aligning therapeutic and 
diagnostic test with clinical 
practice for achieving commercial 
success: Celsentri/Selzentry®
Celsentri® belongs to a class of anti-retrovi-
rals referred to as CCR5 antagonists. CCR5 
antagonists prevent the binding of HIV to the 
CCR5 co-receptor present on the surface of 
the CD4+ T cell, thereby preventing the virus 
from entering these cells and the resultant vi-
ral replication. Celsentri®’s targeted activity 
against CCR5 tropic virus requires that pa-
tient responders be identified via a tropism 
diagnostic prior to therapy initiation. When 
the product was first launched, the only va-
lidated tropism diagnostic was offered by a 
single diagnostic manufacturer. Even though 
Celsentri® was a very targeted therapy with 
proven efficacy, the implication of having the 
tropism assay done by a single assay manu-
facturer, resulted in a logistical challenge of 
having a blood sample drawn, having it ship-
ped across continents and waiting for confir-
mation prior to administration of treatment; 
this resulted in limited uptake and commer-
cial success. This identified limitation points 
to the inherent need for a diagnostic-drug 
combination that can be co-administered, 
with the drug administration following con-
firmation of diagnosis by the companion 
diagnostic that is available widely and con-
ducted with minimal logistical hurdles, ensu-
ring compatibility with clinical practice.
COMMERCIAL AND MARKET 
ACCESS CONSIDERATIONS
Commercial development of therapeutics de-
veloped with a Precision Medicine approach 
requires careful thought. They may command 
an attractive price and greater reimbursement 
due to enhanced value to patients and payers, 
improved patient compliance and fewer failu-
res. There may also be less adverse events and 
hence decreased potential for market withdra-
wal and label restrictions. These advantages, 
however, are balanced by a more fragmented 
market that may limit sales potential.
For these reasons, it is critical to build a 
convincing case for the clinical benefit and 
therapeutic index of the medicine in the de-
fined patient population. Such a case could 
be strengthened through the health economic 
and/or health technology assessments increa-
singly used by public health bodies to support 
reimbursement recommendations for medici-
nes and devices. From a payer perspective, 
there are many potential benefits of Precision 
Medicine that might increase the value. Be-
nefits include improved risk estimates and 
optimized treatment as well as diagnostics or 
other tests that can identify high risk patients 
at an early stage of disease. Importantly, the 
ability to identify the patients who are more 
likely to respond to treatment or less likely 
to experience adverse events will be a strong 
driver of value as payers balance mounting 
healthcare costs versus healthcare funding 
constraints and decreasing budgets.
Even though the promise of Precision Me-
dicine is certainly there, there are significant 
hurdles that need to be overcome from a po-
licy and infrastructure perspective, for the 
promise to be realized:
First of all, evaluation of the diagnostic and 
therapy are currently conducted separately by 
regulatory and reimbursement agencies. This 
results in disconnect in the assessment, and 
creates a potential hurdle for the full realiza-
tion of synergistic value from a precision me-
dicine approach, as diagnostics by themsel-
ves may not be cost-effective. In addition, 
the pathway for assessment of diagnostics is 
relatively unclear, leading to sometimes pro-
tracted time for approval and delay in the me-
dicine reaching the appropriate patient.
Second, current Health Technology Asses-
sment methods and reimbursement models 
do not have a mechanism of uniformly asses-
sing diagnostics, and appropriately linking 
payment for diagnostics to the value genera-
ted. This has been apparent due to lack of or in 
some cases reduction in reimbursement rates 
for diagnostics measures or scans (e.g. bone 
density scans), with the pharmaceutical ma-
nufacturer picking up the costs for diagnostic 
testing in many cases (e.g. KRAS tests).
Third, in absence of a clear direction and 
incentive to simultaneously develop the me-
dicine and the diagnostic, pharmaceutical 
manufacturers have been reticent to setup 
co-development platforms and infrastructure, 
which would facilitate the development and 
value demonstration of the diagnostic-medi-
cine package.
Fourth, lack of clear intellectual property de-
signations for diagnostic tests has resulted in 
limited interest on behalf of diagnostic ma-
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nufacturers, to comprehensibly develop and 
demonstrate value of the tests.
Finally, today’s episode-of-care based reim-
bursement systems do not create appropriate 
incentives for adopting a targeted approach 
to treatment in clinical practice; a move to-
wards outcome-based reimbursement would 
be required for adoption of diagnostics and 
the full benefits of Precision Medicine to be 
realized.
Precision Medicine certainly holds a lot of 
promise to change the way pharmaceuticals 
are developed and delivered; however, a lot 
of progress still needs to be made within the 
regulatory, reimbursement and policy fra-
mework for this promise to become a reality.
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